What topics should I discuss with a 15-year-old female who is considering the Depo-Provera (medroxyprogesterone acetate) injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Counseling a 15-Year-Old About Depo-Provera

You should counsel this adolescent about bleeding irregularities (which occur in nearly all patients initially), potential weight gain (particularly in the first 6 months), bone density effects requiring calcium/vitamin D supplementation, and the delayed return to fertility (9-18 months), while emphasizing that pre-injection counseling significantly improves continuation rates. 1

Critical Discussion Points

Bleeding Pattern Changes (Most Important for Continuation)

  • Nearly all patients experience menstrual irregularities initially 1
  • Irregular bleeding typically improves over time and often progresses to amenorrhea (which is not harmful) 1, 2
  • Studies demonstrate patients are more likely to continue DMPA if counseled about these effects BEFORE the first injection 1
  • This is the most common reason for discontinuation, making pre-counseling essential

Weight Gain Risk

  • 21% of adolescents experience "early weight gain" (>5% increase at 6 months) 1
  • Early gainers at 6 months had mean BMI increase of 7.6 vs 2.3 for non-early gainers over 18 months 1
  • Consider alternatives to DMPA if she has eating disorders, obesity concerns, or conditions requiring chronic corticosteroids 1
  • Weight gain at 6 months strongly predicts future excessive weight gain 3

Bone Health Requirements (Adolescent-Specific Concern)

All adolescent DMPA users must be counseled to: 1

  • Take 1300 mg calcium daily (food and/or supplements)
  • Take 600 IU vitamin D daily
  • Participate in regular weight-bearing exercise
  • Avoid smoking and alcohol

The FDA black-box warning about bone mineral density exists 3, but subsequent data show substantial BMD recovery after discontinuation 3. ACOG does not recommend limiting use to 2 years or routine bone density monitoring 3, recognizing that pregnancy risks outweigh theoretical bone concerns.

Fertility Considerations

  • Delayed return to fertility is typical: 9-18 months after last injection 1
  • However, this delay "does not usually pose a major deterrent" for adolescent patients 1
  • Emphasize this is reversible, just delayed

Practical Advantages to Highlight

  • Injection every 13 weeks (can extend to 15 weeks) 1
  • No daily adherence required (major advantage over pills)
  • Improves dysmenorrhea 1
  • Protects against iron-deficiency anemia and endometrial cancer 1
  • Safe for most chronic illnesses 1

STI Protection

Emphasize that DMPA provides NO protection against STIs 3

  • Condoms must be used consistently for STI prevention
  • Use backup method (condoms or abstinence) for first 7 days after injection 3

When to Consider Alternatives

More strongly encourage alternatives if she has: 1

  • Eating disorders
  • Obesity or significant weight concerns
  • Chronic corticosteroid use
  • Chronic alcohol or tobacco use
  • Concerns about irregular bleeding

In these situations, discuss IUDs or implants as LARC alternatives with higher continuation rates (75%+ at 1 year for IUDs 1) and fewer metabolic concerns.

Common Pitfall to Avoid

Do not require a second visit for DMPA initiation - this serves as a barrier to contraceptive care, with only 68% receiving DMPA at return visits and 7% becoming pregnant before returning 4. Provide same-day initiation when possible.

Additional Counseling Points

  • Other possible side effects: headache, breast tenderness, hair loss, libido changes 3
  • Recent data suggest possible increased meningioma risk with >4 years use or starting after age 31 5, though number needed to harm is 1,152 patients
  • Self-administration of subcutaneous DMPA is now an option that improves continuation rates 6

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.